tiprankstipranks
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
US Market
JAZZ
Jazz Pharmaceuticals
RESEARCH TOOLSreports
Want to see JAZZ full AI Analyst Report?

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

1,894 Followers
See the Price Targets and Ratings of:

JAZZ Analyst Ratings

Strong Buy
14Ratings
Strong Buy
13 Buy
1 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Jazz
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JAZZ Stock 12 Month Forecast

Average Price Target

$258.83
▲(27.24% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $258.83 with a high forecast of $307.00 and a low forecast of $226.00. The average price target represents a 27.24% change from the last price of $203.42.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"107":"$107","308":"$308","157.25":"$157.3","207.5":"$207.5","257.75":"$257.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":307,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$307.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":258.8333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$258.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":226,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$226.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[107,157.25,207.5,257.75,308],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,232.64,238.35999999999999,244.07999999999998,249.79999999999998,255.51999999999998,261.24,266.96,272.68,278.4,284.12,289.84,295.56,301.28,{"y":307,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,232.64,234.65487179487178,236.66974358974358,238.68461538461537,240.69948717948716,242.71435897435896,244.72923076923075,246.74410256410255,248.75897435897434,250.77384615384614,252.78871794871793,254.80358974358973,256.8184615384615,{"y":258.8333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,232.64,232.12923076923076,231.61846153846153,231.1076923076923,230.59692307692308,230.08615384615385,229.57538461538462,229.06461538461537,228.55384615384614,228.0430769230769,227.53230769230768,227.02153846153846,226.51076923076923,{"y":226,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":108.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.52,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.27,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.72,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":232.64,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$307.00Average Price Target$258.83Lowest Price Target$226.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on JAZZ
David Amsellem
Piper Sandler
Piper Sandler
$301
Buy
47.97%
Upside
Reiterated
06/02/26
Piper Sandler Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
J.P. Morgan Analyst forecast on JAZZ
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/02/26
Jessica Fye Reaffirms Buy on Jazz Pharmaceuticals, Citing Blockbuster Potential for Zanidatamab in First-Line HER2-Positive Gastric and Esophageal Cancers
Bernstein Analyst forecast on JAZZ
Unknown Analyst
Bernstein
Not Ranked
Bernstein
―
Hold
―
Reiterated
06/01/26
Jazz Pharmaceuticals (JAZZ) Gets a Hold from Bernstein
Barclays Analyst forecast on JAZZ
Etzer Darout
Barclays
Barclays
$234→$253
Buy
24.37%
Upside
Reiterated
05/27/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Barclays
UBS Analyst forecast on JAZZ
Ashwani Verma
UBS
UBS
$188→$307
Buy
50.92%
Upside
Upgraded
05/19/26
Jazz Pharmaceuticals upgraded to Buy from Neutral at UBSJazz Pharmaceuticals upgraded to Buy from Neutral at UBS
Needham Analyst forecast on JAZZ
Ami Fadia
Needham
Needham
$255
Buy
25.36%
Upside
Reiterated
05/11/26
Needham Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
RBC Capital Analyst forecast on JAZZ
Leonid Timashev
RBC Capital
RBC Capital
$195→$258
Buy
26.83%
Upside
Assigned
05/06/26
Jazz Pharmaceuticals (JAZZ) Gets a Buy from RBC Capital
Stifel Nicolaus Analyst forecast on JAZZ
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$230
Buy
13.07%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), SOPHiA GENETICS (NASDAQ: SOPH) and Solventum Corporation (NYSE: SOLV)
Wells Fargo Analyst forecast on JAZZ
Mohit Bansal
Wells Fargo
Wells Fargo
$250→$265
Buy
30.27%
Upside
Reiterated
05/06/26
Wells Fargo Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Raymond James Analyst forecast on JAZZ
Tiago Fauth
Raymond James
Raymond James
$239
Buy
17.49%
Upside
Reiterated
05/06/26
Raymond James Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Robert W. Baird Analyst forecast on JAZZ
Brian Skorney
Robert W. Baird
Robert W. Baird
$209→$252
Buy
23.88%
Upside
Reiterated
05/06/26
Jazz Pharmaceuticals price target raised to $252 from $209 at BairdJazz Pharmaceuticals price target raised to $252 from $209 at Baird
TD Cowen Analyst forecast on JAZZ
Joseph Thome
TD Cowen
TD Cowen
$220→$275
Buy
35.19%
Upside
Assigned
05/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Morgan Stanley Analyst forecast on JAZZ
Sean Laaman
Morgan Stanley
Morgan Stanley
$226→$245
Buy
20.44%
Upside
Reiterated
05/05/26
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (NASDAQ: JAZZ), Dianthus Therapeutics (NASDAQ: DNTH) and Waters (NYSE: WAT)
Deutsche Bank Analyst forecast on JAZZ
David Hoang
Deutsche Bank
Deutsche Bank
$225→$226
Buy
11.10%
Upside
Reiterated
03/05/26
Jazz Pharmaceuticals price target raised to $226 from $225 at Deutsche BankJazz Pharmaceuticals price target raised to $226 from $225 at Deutsche Bank
Jefferies Analyst forecast on JAZZ
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$225
Buy
10.61%
Upside
Reiterated
02/25/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on JAZZ
David Amsellem
Piper Sandler
Piper Sandler
$301
Buy
47.97%
Upside
Reiterated
06/02/26
Piper Sandler Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
J.P. Morgan Analyst forecast on JAZZ
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/02/26
Jessica Fye Reaffirms Buy on Jazz Pharmaceuticals, Citing Blockbuster Potential for Zanidatamab in First-Line HER2-Positive Gastric and Esophageal Cancers
Bernstein Analyst forecast on JAZZ
Unknown Analyst
Bernstein
Not Ranked
Bernstein
―
Hold
―
Reiterated
06/01/26
Jazz Pharmaceuticals (JAZZ) Gets a Hold from Bernstein
Barclays Analyst forecast on JAZZ
Etzer Darout
Barclays
Barclays
$234→$253
Buy
24.37%
Upside
Reiterated
05/27/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Barclays
UBS Analyst forecast on JAZZ
Ashwani Verma
UBS
UBS
$188→$307
Buy
50.92%
Upside
Upgraded
05/19/26
Jazz Pharmaceuticals upgraded to Buy from Neutral at UBSJazz Pharmaceuticals upgraded to Buy from Neutral at UBS
Needham Analyst forecast on JAZZ
Ami Fadia
Needham
Needham
$255
Buy
25.36%
Upside
Reiterated
05/11/26
Needham Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
RBC Capital Analyst forecast on JAZZ
Leonid Timashev
RBC Capital
RBC Capital
$195→$258
Buy
26.83%
Upside
Assigned
05/06/26
Jazz Pharmaceuticals (JAZZ) Gets a Buy from RBC Capital
Stifel Nicolaus Analyst forecast on JAZZ
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$230
Buy
13.07%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), SOPHiA GENETICS (NASDAQ: SOPH) and Solventum Corporation (NYSE: SOLV)
Wells Fargo Analyst forecast on JAZZ
Mohit Bansal
Wells Fargo
Wells Fargo
$250→$265
Buy
30.27%
Upside
Reiterated
05/06/26
Wells Fargo Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Raymond James Analyst forecast on JAZZ
Tiago Fauth
Raymond James
Raymond James
$239
Buy
17.49%
Upside
Reiterated
05/06/26
Raymond James Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Robert W. Baird Analyst forecast on JAZZ
Brian Skorney
Robert W. Baird
Robert W. Baird
$209→$252
Buy
23.88%
Upside
Reiterated
05/06/26
Jazz Pharmaceuticals price target raised to $252 from $209 at BairdJazz Pharmaceuticals price target raised to $252 from $209 at Baird
TD Cowen Analyst forecast on JAZZ
Joseph Thome
TD Cowen
TD Cowen
$220→$275
Buy
35.19%
Upside
Assigned
05/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Morgan Stanley Analyst forecast on JAZZ
Sean Laaman
Morgan Stanley
Morgan Stanley
$226→$245
Buy
20.44%
Upside
Reiterated
05/05/26
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (NASDAQ: JAZZ), Dianthus Therapeutics (NASDAQ: DNTH) and Waters (NYSE: WAT)
Deutsche Bank Analyst forecast on JAZZ
David Hoang
Deutsche Bank
Deutsche Bank
$225→$226
Buy
11.10%
Upside
Reiterated
03/05/26
Jazz Pharmaceuticals price target raised to $226 from $225 at Deutsche BankJazz Pharmaceuticals price target raised to $226 from $225 at Deutsche Bank
Jefferies Analyst forecast on JAZZ
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$225
Buy
10.61%
Upside
Reiterated
02/25/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jazz Pharmaceuticals

3 Months
Joon LeeTruist Financial
Success Rate
14/21 ratings generated profit
67%
Average Return
+4.28%
Copying Joon Lee's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +4.28% per trade.
1 Year
Joseph ThomeTD Cowen
Success Rate
17/18 ratings generated profit
94%
Average Return
+41.03%
Copying Joseph Thome's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +41.03% per trade.
2 Years
Joseph ThomeTD Cowen
Success Rate
18/18 ratings generated profit
100%
Average Return
+66.44%
Copying Joseph Thome's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +66.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JAZZ Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
2
2
0
0
0
Buy
24
27
22
25
23
Hold
0
0
0
3
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
29
22
28
27
In the current month, JAZZ has received 23 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. JAZZ average Analyst price target in the past 3 months is 258.83.
Each month's total comprises the sum of three months' worth of ratings.

JAZZ Financial Forecast

JAZZ Earnings Forecast

Next quarter’s earnings estimate for JAZZ is $6.18 with a range of $5.53 to $7.07. The previous quarter’s EPS was $6.34. JAZZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.
Next quarter’s earnings estimate for JAZZ is $6.18 with a range of $5.53 to $7.07. The previous quarter’s EPS was $6.34. JAZZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.

JAZZ Sales Forecast

Next quarter’s sales forecast for JAZZ is $1.11B with a range of $1.07B to $1.16B. The previous quarter’s sales results were $1.07B. JAZZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.
Next quarter’s sales forecast for JAZZ is $1.11B with a range of $1.07B to $1.16B. The previous quarter’s sales results were $1.07B. JAZZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.

JAZZ Stock Forecast FAQ

What is JAZZ’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 258.83.
    What is JAZZ’s upside potential, based on the analysts’ average price target?
    Jazz Pharmaceuticals has 27.24% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is JAZZ a Buy, Sell or Hold?
          Jazz Pharmaceuticals has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Jazz Pharmaceuticals’s price target?
            The average price target for Jazz Pharmaceuticals is 258.83. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $307.00 ,the lowest forecast is $226.00. The average price target represents 27.24% Increase from the current price of $203.42.
              What do analysts say about Jazz Pharmaceuticals?
              Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of JAZZ?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.